Home
About
Overview
Sharing Data
ORCID
Help
History (4)
Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life.
Rehospitalization for respiratory syncytial virus among premature infants.
The critical role of population-based epidemiology in cost-effectiveness research.
See All 4 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999 Sep; 104(3 Pt 1):419-27.
View in:
PubMed
subject areas
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cost of Illness
Cost-Benefit Analysis
Decision Support Techniques
Drug Costs
Hospital Costs
Hospitalization
Humans
Immunoglobulins, Intravenous
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases
Palivizumab
Respiratory Syncytial Virus Infections
Respiratory Syncytial Viruses
Risk Factors
authors with profiles
Tracy Ann Lieu, MD, MPH